The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.

ABSTRACT:

Background

Although high-grade salivary gland cancers (SGCs) often express androgen receptor (AR) and/or HER-2/neu, therapeutically targeting these receptors in SGC remains investigational. We investigated the prevalence of receptor expression and the benefit of adjuvant HER-2 directed therapy in the high-risk postoperative setting and explored the clinical utility of sequentially targeting these receptors in the setting of advanced disease.

Materials and methods

We clinically annotated 95 patients with SGC (excluding adenoid cystic carcinoma) treated at our institution from 2002 to 2019 and recorded AR, HER-2/neu status, and tumor genomic profiling results when available. Clinicopathologic information was then integrated with outcomes.

Results

Of 95 patients, most ha

SUBMITTER: Hanna GJ 

PROVIDER: S-EPMC7356716 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature